

# FORM 11

## NOTICE OF PROPOSED STOCK OPTION GRANT OR AMENDMENT

Name of Listed Issuer: Kaneh Bosm Biotechnology Inc. (the "Issuer").

Trading Symbol: KBB

Date: June 26, 2018

### 1. New Options Granted:

Date of Grant: June 22, 2018

Name of Optionee	Position (Director/ Officer/ Employee/ Consultant/ Management Company)	Insider Yes or No?	No. of Optioned Shares	Exercise Price	Expiry Date	No. of Options Granted in Past 12 Months
Rudy de Jonge	Director	Yes	700,000	\$0.51	June 21, 2023	400,000
Michael Martinz	Director	Yes	200,000	\$0.51	June 21, 2023	Nil
Kent Ausburn	Director	Yes	100,000	\$0.51	June 21, 2023	Nil
Johannes van der Linde	Consultant	No	2,091,911	\$0.51	June 21, 2023	Nil
Camden Ventures Inc.	Consultant	No	2,250,000	\$0.51	June 21, 2023	Nil
Fer-De-Lance Capital Corp.	Consultant	No	2,250,000	\$0.51	June 21, 2023	Nil
<b>Total</b>			<b>7,591,911</b>			

Total Number of optioned shares proposed for acceptance: 7,591,911

**2. Other Presently Outstanding Options: 2,000,000**

<b>Name of Optionee</b>	<b>No. of Optioned Shares</b>	<b>Exercise Price</b>	<b>Original Date of Grant</b>	<b>Expiry Date</b>
Kent Ausburn	50,000	\$0.20	Jan 23, 2014	Jan 23, 2019
Michael Martinz	150,000	\$0.20	April 4, 2014	April 4, 2019
Brian O'Dae	100,000	\$0.44	July 30, 2014	July 30, 2019
Daphne Killas	50,000	\$0.20	June 29, 2016	June 29, 2021
James Vincent Souza	50,000	\$0.20	June 29, 2016	June 29, 2021
Kent Ausburn	200,000	\$0.20	June 29, 2016	June 29, 2021
Boddy & Co Investments Ltd.	200,000	\$0.33	Dec 18, 2017	Dec 18, 2019
David DesLauriers	400,000	\$0.33	Dec 18, 2017	Dec 18, 2019
Michael DesLauriers	400,000	\$0.33	Dec 18, 2017	Dec 18, 2019
Rudy de Jonge	400,000	\$0.33	Dec 18, 2017	Dec 18, 2019
<b>Total</b>	<b>2,000,000</b>			

**3. Additional Information**

- (a) If shareholder approval was required for the grant of options (including prior approval of a stock option plan), state the date that the shareholder meeting approving the grant was or will be held.

Shareholder approval for the 10% rolling stock option plan was received on March 22, 2018

- (b) State the date of the news release announcing the grant of options.

June 22, 2018

- (c) State the total issued and outstanding share capital at the date of grant or amendment.

96,219,108

- (d) State, as a percentage of the issued and outstanding shares of the Issuer indicated in (c) above, the aggregate number of shares that are subject to incentive stock options, including new options, amended options and other presently outstanding options.

99.68%

- (e) If the new options are being granted pursuant to a stock option plan, state the number of remaining shares reserved for issuance under the plan.

Nil

- (f) If the Issuer has completed a public distribution of its securities within 90 days of the date of grant, state the per share price paid by the public investors.

Not applicable.

- (g) Describe the particulars of any proposed material changes in the affairs of the Issuer.

There are no proposed material changes in the affairs of the Issuer.

**4. Certificate of Compliance**

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 11 Notice of Proposed Stock Option Grant or Amendment is true.

Dated: June 26, 2018\_\_\_\_\_.

Eugene Beukman  
Name of Director or Senior  
Officer

"Eugene Beukman"  
Signature

Director  
Official Capacity